Market Research Report
Epiomic Epidemiology Series: Mucopolysaccharidosis-II (MPS-II) Hunter Syndrome Forecast in 26 Major Markets 2017-2027
|Published by||Black Swan Analysis||Product code||436082|
|Published||Content info||102 Pages
|Epiomic Epidemiology Series: Mucopolysaccharidosis-II (MPS-II) Hunter Syndrome Forecast in 26 Major Markets 2017-2027|
|Published: February 1, 2017||Content info: 102 Pages||
Black Swan Analysis Epiomic™ Epidemiology Series Forecast Report on MPS-II (Hunter Syndrome) in 26 Major Markets
Mucopolysaccharidosis-II, also known as MPS-II or Hunter syndrome, is part of the Mucopolysaccharidoses (MPS) disorders - a group of rare genetic disorders caused by deficiencies of lysosomal enzymes. MPS II is caused by deficiency of the lysosomal enzyme iduronate-2-sulphatase (IDS gene) leading to progressive accumulation of glycosaminoglycans in nearly all cell types, tissues and organs. It is a progressively debilitating disorder; however, the rate of progression varies among affected individuals.
Unlike other MPS disorders, MPS-II nearly exclusively affects males since it is an X-linked disorder. Few cases of females have been noted; however these cases tend to milder and very rare. MPS-II is typically classified as Severe (with neurological / cognitive impairment) or attenuated / mild (without neurological / cognitive impairment).
This report provides the current prevalent population for MPS-II across 26 Major Markets (USA, Canada, France, Germany, Italy, Spain, UK, Ireland, Brazil, Mexico, Japan, South Korea, China, India, Australia, Netherlands, Denmark, Sweden, Norway, Turkey, Portugal, Bulgaria, Poland, Estonia, Russia and Czech Republic) split by 5-year age cohort. Along with the current prevalence, the report also contains a disease overview of the risk factors, disease diagnosis and prognosis along with specific variations by geography and ethnicity.
Providing a value-added level of insight from the analysis team at Black Swan, several of the main symptoms and co-morbidities of MPS-II have been quantified and presented alongside the overall prevalence figures. These sub-populations within the main disease are also included at a country level across the 10-year forecast snapshot.
This report is built using data and information sourced from the proprietary Epiomic patient segmentation database. To generate accurate patient population estimates, the Epiomic database utilises a combination of several world class sources that deliver the most up to date information form patient registries, clinical trials and epidemiology studies. All of the sources used to generate the data and analysis have been identified in the report.